Deferred Income Tax Liabilities, Net in USD of BIO-RAD LABORATORIES, INC. from Q4 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Summary
Bio Rad Laboratories, Inc. quarterly Deferred Income Tax Liabilities, Net history and change rate from Q4 2019 to Q3 2025.
  • Bio Rad Laboratories, Inc. Deferred Income Tax Liabilities, Net for the quarter ending 30 Sep 2025 was $873M, a 18.9% decline year-over-year.
Deferred Income Tax Liabilities, Net, Quarterly (USD)
Deferred Income Tax Liabilities, Net, YoY Quarterly Change (%)

BIO-RAD LABORATORIES, INC. Quarterly Deferred Income Tax Liabilities, Net (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $873M -$203M -18.9% 30 Sep 2025 10-Q 29 Oct 2025
Q2 2025 $961M +$82.5M +9.4% 30 Jun 2025 10-Q 31 Jul 2025
Q1 2025 $841M -$700M -45.4% 31 Mar 2025 10-Q 01 May 2025
Q4 2024 $818M -$658M -44.6% 31 Dec 2024 10-Q 29 Oct 2025
Q3 2024 $1.08B -$293M -21.4% 30 Sep 2024 10-Q 31 Oct 2024
Q2 2024 $878M -$523M -37.3% 30 Jun 2024 10-Q 02 Aug 2024
Q1 2024 $1.54B -$229M -12.9% 31 Mar 2024 10-Q 08 May 2024
Q4 2023 $1.48B -$295M -16.7% 31 Dec 2023 10-K 14 Feb 2025
Q3 2023 $1.37B -$115M -7.75% 30 Sep 2023 10-Q 27 Oct 2023
Q2 2023 $1.4B -$212M -13.1% 30 Jun 2023 10-Q 04 Aug 2023
Q1 2023 $1.77B -$226M -11.3% 31 Mar 2023 10-Q 05 May 2023
Q4 2022 $1.77B -$1.29B -42.2% 31 Dec 2022 10-K 16 Feb 2024
Q3 2022 $1.48B -$2.08B -58.4% 30 Sep 2022 10-Q 28 Oct 2022
Q2 2022 $1.61B -$929M -36.5% 30 Jun 2022 10-Q 29 Jul 2022
Q1 2022 $2B -$310M -13.5% 31 Mar 2022 10-Q 29 Apr 2022
Q4 2021 $3.06B +$988M +47.6% 31 Dec 2021 10-K 17 Feb 2023
Q3 2021 $3.57B +$1.73B +93.7% 30 Sep 2021 10-Q 29 Oct 2021
Q2 2021 $2.54B +$1.09B +74.5% 30 Jun 2021 10-Q 30 Jul 2021
Q1 2021 $2.31B +$1.15B +98.6% 31 Mar 2021 10-Q 30 Apr 2021
Q4 2020 $2.08B +$1.08B +108% 31 Dec 2020 10-K 11 Feb 2022
Q3 2020 $1.84B 30 Sep 2020 10-Q 30 Oct 2020
Q2 2020 $1.46B 30 Jun 2020 10-Q 31 Jul 2020
Q1 2020 $1.16B 31 Mar 2020 10-Q 08 May 2020
Q4 2019 $998M 31 Dec 2019 10-K 16 Feb 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.